

Johnson & Johnson Innovative Medicine Pipeline

Key Events in 2026*

POTENTIAL APPROVALS US/EU

PLANNED SUBMISSIONS US/EU

POTENTIAL CLINICAL DATA PRESENTATIONS¹

Phase III

Phase I/ II

US **TREMFYA (guselkumab)**
Psoriatic Arthritis Structural
Damage (APEX)

US **nipocalimab**
Warm Autoimmune Hemolytic
Anemia (ENERGY)

US **ERLEADA (apalutamide)**
EU Localized Prostate Cancer
(ATLAS)

icotrokinra
Psoriasis (ICONIC-ADVANCE
1&2 Update)

ERLEADA (apalutamide)
Localized Prostate Cancer (ATLAS)

JNJ-4804 Co-antibody Therapy
Ulcerative Colitis (DUET-UC)

US **icotrokinra**
EU Psoriasis (ICONIC)

US **CAPLYTA (lumateperone)**
Bipolar Mania

US **ERLEADA (apalutamide)**
EU High Risk Prostate Cancer
(PROTEUS)

icotrokinra
Psoriasis (ICONIC-ASCEND)

ERLEADA (apalutamide)
High Risk Prostate Cancer
(PROTEUS)

JNJ-4804 Co-antibody Therapy
Crohn's Disease (DUET-CD)

EU **AKEEGA (niraparib/abiraterone)**
M1 Metastatic Castration-
Sensitive Prostate Cancer
(AMPLITUDE)

US **bleximenib**
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)

icotrokinra
Psoriatic Arthritis (ICONIC-PsA)

TALVEY (talquetamab)
Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)

JNJ-4804 Co-antibody Therapy
Psoriatic Arthritis (AFFINITY)

US **DARZALEX (daratumumab)**
Frontline multiple myeloma
transplant ineligible (CEPHEUS)

US **TALVEY (talquetamab)**
EU Relapsed Refractory Multiple
Myeloma A-CD38 Naïve
(MonumenTAL-3)

icotrokinra
Psoriasis (ICONIC-TOTAL
Update)

TECVAYLI (teclistamab)
Relapsed Refractory Multiple
Myeloma CD38 exposed (MajesTEC-
9)

nipocalimab
Systemic Lupus Erythematosus
(JASMINE)

US **TECVAYLI (teclistamab)**
EU Multiple Myeloma 1-3PLs
(MajesTEC-3)

US **TECVAYLI (teclistamab)**
EU Relapsed Refractory Multiple
Myeloma CD38 exposed
(MajesTEC-9)

CAPLYTA (lumateperone)
Bipolar Mania (ITI-007-452)

**INLEXZO (gemcitabine intravesical
delivery system)**
High Risk Non Muscle Invasive
Bladder Cancer BCG Experienced
(SunRISe-5)

bleximenib
Relapsed Refractory Acute
Myeloid Leukemia (cAMeLot-1)

✓ EU **TECVAYLI (teclistamab)**
Multiple Myeloma 1-3PLs
(MajesTEC-3)

JNJ-1887 sCD59
Geographic Atrophy (PARASOL)

US **INLEXZO (gemcitabine
intravesical delivery system)**
EU High Risk Non Muscle Invasive
Bladder Cancer BCG
Experienced (SunRISe-5)

1. In order to be on key events clinical presentation, data must be presented at a major medical meeting.

*This is not a fully exhaustive list of all pipeline programs and assets. The pipeline includes assets currently progressing through clinical trials as well as those under review by regulatory bodies. Inclusion in the pipeline is based on the current status of these programs and assets and does not guarantee continued investment. This information is as of January 21, 2026 to the best of the Company's knowledge. Johnson & Johnson assumes no obligation to update this information.

✓ = Achieved

